Leader Capital Markets Remains Bullish on Teva Pharmaceutical Industries (TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best strong buy healthcare stocks to buy now. In a report released on July 21, Sabina Levi from Leader Capital Markets maintained a Buy rating on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a price target of ILA9,300.00.

In other news, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced a strategic partnership with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on June 16. The partnership aims at the development of investigational TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy.

Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) internally developed ATTENUKINE technology provides a new mechanism of action that potentially offers low toxicity and high efficacy in a range of oncology indications.

The terms of the agreement focus on the acceleration of clinical data generation, granting Fosun Pharma “an exclusive license to develop, manufacture and commercialize TEV-56278 in the Chinese mainland, Hong Kong Special Administrative Region (SAR), Macau SAR and Taiwan region, and select Southeast Asian countries”.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, produces, and sells medicines. Its operations are divided into the US, Europe, and International Markets geographical segments. Each business segment covers the entire product portfolio in that region, including specialty, generics, and over-the-counter (OTC) products.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.